頁籤選單縮合
題 名 | 可由人尿中提煉的仙丹--MCSF之基礎與臨床應用=Basics and Clinical Applications of M-CSF from Human Urine |
---|---|
作 者 | 柳內正也; 李連滋; 江淑芬; | 書刊名 | 化工資訊月刊 |
卷 期 | 12:8 1998.08[民87.08] |
頁 次 | 頁44-52 |
分類號 | 415.6 |
關鍵詞 | 人尿; 造血因子; MCSF; |
語 文 | 中文(Chinese) |
中文摘要 | EPO和CSF是與血液方面,有關的重要生長因子,前者為紅血球的生長因子,而後 者CSF為顆粒球、單球等的生長因子。CSF又分成G-CSF、M-CSF和GM-CSF等三類,其中G-CSF 被公認將是公元2000年時最暢銷的生技藥品之一。 本文主講者深入淺出之精闢演講,可知雖然投予G-CSF可使白血球數目明顯增加,而大 量投予M-CSF後,白血球數目並未增加;但在臨床上,G-CSF在感染症防止效果、癌症治療時 程縮短和其存活率增加上無法有效的改善,而M-CSF在感染症防止上有15-20%的改善,癌症 治療時程可縮短17天的療程,癌症存活率可增加15-55%,因此M-CSF在臨床上有其重要的意 義。除了應用在治療癌症外,M-CSF可望用於不孕症、骨質疏鬆症及防止血管栓塞等。 |
英文摘要 | Erythropoietin (EPO) and colony stimulating factor (CSF) are two important stimulating factors for red blood cells and white blood cells, respectively. G-CSF, M-CSF and GM-CSF are all colony stimulating factors. As generally accepted, G-CSF is the most highly promising bio-pharmaceuticals by the year 2000. According to the project leadder of M-CSF from the laboratory to clinical trials, M-CSF and G-CSF affect cancer patients to varying extents. In addition, G-CSF can increase the number of white blood cells in blood, which is considered an index of CSF's efficacy by doctors; meanwhile M-CSF is not. Such an increase is attributed to the large market demand for G-CSF, which is ten times larger than that of M-CSF, However, M-CSF is better than G-CSF in that it does not show any significance in clinical trials. Not only can M-CSF prevent the infection by 15-20%, but it also reduces the therapeutic time of cancer by 17 days. Importantly, M-CSF can increase the disease-free survival by 15-55%. Moreover, M-CSF can also be applied to the diseases of barren, osteoporosis and clotting of blood vessels. |
本系統中英文摘要資訊取自各篇刊載內容。